|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1986, 1987, 1990, 1995, 1997, 1999, 2002, 2007, 2009, 2012
NORD is very grateful to Phyllis W. Speiser, MD, Chief, Division of Pediatric Endocrinology, Cohen Children's Medical Center of NY; Professor of Pediatrics, Hofstra North Shore LIJ School of Medicine, for assistance in the preparation of this report.
Congenital adrenal hyperplasia (CAH) is a group of rare autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH effects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, which gage the body's response to illness or injury, mineralocorticoids, which regulate salt and water levels, and androgens, which are male sex hormones. An enzyme deficiency will make the body unable to produce one or more of these hormones, which will result in the overproduction of another in order to compensate for the loss.
The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different levels of the enzyme. and produce a spectrum of effects. CAH due to 21-hydroxylase deficiency is responsible for 95% of all cases of CAH and is broken down further into two subcategories: classical CAH, which can be divided further into the salt-losing form or the simple-virilizing form, and non-classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated. Non-classical CAH is milder, and may or may not present symptoms. Since the absence of 21-hydroxylase makes these individuals unable to make the hormone cortisol and, in the case of salt-losing CAH, aldosterone, the body produces more androgens which cause a variety of symptoms such as abnormal sexual development.
There are other much rarer forms of CAH as well, including 11-Beta hydroxylase deficiency, 17a-hydroxylase deficiency, 3-Beta-hydroxysteroid dehydrogenase deficiency, and congenital lipoid adrenal hyperplasia, which all present different symptoms.
Although CAH is not curable, as long as patients receive adequate care and treatment, they can go on to lead normal lives.
Many individuals with CAH present with abnormally enlarged adrenal glands (hyperplastic adrenomegaly) that produce excessive amounts of androgens (male steroid hormones) leading to abnormal sexual development in females affected with the disease. Females with severe or classic virilizing CAH due to 21-hydroxylase deficiency will most likely have ambiguous external genitalia (masculinization or virilization), although they are genetically female and will have normal internal reproductive organs. Males with this type of CAH will not have ambiguous genitalia. Both genders can experience other symptoms such as early onset of puberty, fast body growth, and premature completion of growth leading to short stature, if they are not diagnosed and treated in early life.
About 75% of people with classical CAH due to 21-hydroxylase deficiency also have a deficiency of the hormone aldosterone, leading to the inability to retain salt and water (salt wasting). This results in excessive loss of water (dehydration), low circulating blood volume (hypovolemia), and abnormally low blood pressure (hypotension and shock). Without treatment, this severe form of CAH can lead to profound weakness, vomiting, diarrhea, and circulatory collapse due to adrenal crisis in infancy. The remaining 25% are referred to as simple-virilizers and do not have a problem regulating salt and water levels.
Fortunately in the United States, and in many other developed countries, there is universal newborn screening for CAH due to 21-hydroxylase deficiency, and the vast majority of children are diagnosed and treated early to avoid these complications.
The mild form of 21-hydroxylase deficiency (non-classical CAH) is not life-threatening and is due to a more common genetic mutation. This mild form is not usually detected in our newborn screening programs, and it seldom requires early treatment. Symptoms in later childhood may include premature body hair or acne development. In adolescent females, the most common problems include excessive facial or body hair, menstrual irregularities, and pustular acne. Both genders have normal genitals. A small proportion of the non-classic CAH population has sub-fertility. Patients with CAH may or may not require treatment to improve their quality of life.
Rare forms of CAH:
11-Beta hydroxylase deficiency patients are protected from the symptoms associated with adrenal crisis, although they are subject to others such as hypertension due to salt retention and ambiguous genitalia in females.
17a-hydroxylase deficiency also results in ambiguous external genitalia in males and lack of a pubertal development or menstrual cycles (amenorrhea) in females.
3-Beta-hydroxysteroid dehydrogenase deficiency leads to ambiguous genitalia in males and females. In both genders it can lead to salt-wasting.
Lastly, congenital lipoid adrenal hyperplasia may cause early death due to adrenal crisis. Males have ambiguous genitalia. Both males and females, if they survive, would likely be infertile.
Deletions and mutations in the CYP21A2 gene account for all cases of the 21-hydroxylase deficiency form of CAH. Mutations in the CYP11B1, CYP17A1, HSD3B2 and STAR genes are responsible, respectively, for 11-hydroxylase, 17-hydroxylase, 3-beta-hydroxysteroid dehydrogenase deficiencies, and lipoid adrenal hyperplasia, the other rarer forms of CAH. An additional form of CAH has recently been described called P450 oxidoreductase deficiency. This is caused by lack of a co-factor necessary for the activity of several of the above enzymes, and has a variable presentation. Some cases have been associated with skeletal malformations (one type of Antley-Bixler syndrome).
All forms of CAH are inherited as an autosomal recessive genetic trait. Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
The most common form of CAH, 21 hydroxylase deficiency, affects approximately 1:10,000 to 1:15,000 people in the United States and Europe. Among the Yupik Eskimo, the occurrence of the salt-wasting form of this disorder may be as high as 1 in 282 individuals. Other forms of CAH are much rarer.
Based on small population surveys, non-classical CAH affects approximately 1 in 30 Ashkenazi Jews, 1 in 40 Hispanics, 1 in 50 Yugoslavians, and 1 in 300 Italians. Thus far, about 1 in 100 individuals in the Caucasian non-Jewish groups who have been studied have the non-classical form of this disorder.
Symptoms of the following disorders can be similar to those of congenital adrenal hyperplasia. Comparisons may be useful for a differential diagnosis:
Addison disease is a rare disorder characterized by inadequate production of cortisol, aldosterone, and/or androgens by the outer layer of cells of the adrenal glands (adrenal cortex). The symptoms of classic Addison disease, also known as primary adrenal insufficiency, result from the insufficient production of these hormones. Major symptoms include fatigue, hypotension, salt-craving, abdominal pain, nausea or vomiting, darkened skin color, and absence of body hair. Depressive behavior and mood changes may also occur in some individuals with Addison disease. The symptoms of Addison usually develop slowly, but sometimes can develop rapidly, a serious condition called acute adrenal failure. In most cases, Addison disease most often occurs when the body's immune system mistakenly attacks the adrenal glands causing slowly progressive damage to the adrenal cortex. (For more information on this disorder, choose "Addison" as your search term in the Rare Disease Database.) Since autoimmune disorders often cluster in families and individual patients, people who themselves suffer, or who have family members who suffer from such diseases (eg, type 1 diabetes, Graves disease, lupus) should be screened for Addison disease if they have suggestive symptoms. There are other non-immune forms of adrenal dysfunction, including iatrogenic (caused by medications), inherited, infectious, cancerous and toxic adrenal diseases.
Ovotesticular disorder of sex development (ovotesticular DSD) is a very rare disorder in which an infant is born with the internal reproductive organs (gonads) of both sexes (female ovaries and male testes). The gonads can be any combination of ovary, testes or combined ovary and testes (ovotestes). The external genitalia are usually ambiguous but can range from normal male to normal female. (For more information on this disorder, choose "Ovotesticular disorder of sex development" as your search term in the Rare Disease Database.)
Virilization of female fetuses and children, or accelerated sexual maturity in males, may also result from androgen-producing tumors or exposure to androgenic substances. Genetic defects affecting development of the pituitary, adrenal or gonads (testicles or ovaries) can also result in abnormal sexual development.
All newborns in the United States are screened for 21-hydroxylase deficiency. Non-classic CAH is frequently not detected in the newborn test and therefore, may not be diagnosed until childhood or early adulthood when the patient first starts showing symptoms. Genetic testing for the gene mutations associated with the various forms of CAH is available, but is most often performed when pre-pregnancy genetic counseling is indicated, after an endocrinologist confirms the diagnosis through blood hormone tests, or if results of hormone tests are not definitive.
Prenatal diagnosis is available for couples at risk for having a child affected with CAH using first trimester chorionic villus sampling and testing the fetal DNA for a particular CAH gene mutation known to occur in the family.
If CAH is detected in a fetus, prenatal treatment is a possibility, although it should be regarded as experimental. The oral drug dexamethasone can be given to pregnant women in a subsequent pregnancy if she has given birth to child with severe classical CAH. Such treatment does not prevent or cure the disease, but may lessen the virilization of affected female fetuses. There is limited knowledge about the long-term safety of this procedure, and this should be done only under the supervision of experienced clinicians who report to an ethical review board for human studies.
Monitoring hormones levels in individuals with CAH is crucial throughout their post-natal life. Height and weight are other important aspects that need to be monitored in order to know if treatment should be adjusted, particularly in children. Monitoring bone age is an additional tool to determine if the child is undergoing proper physical maturation. A simple x-ray of the hand can show the growth centers and provide an estimate of predicted adult height. As individuals mature, the growth centers change and have characteristic appearances at different ages. Too much sex hormone secretion can cause bones to age more rapidly, and treatment can slow this progression, if caught early.
Treatment of CAH varies greatly depending on the type and severity. CAH cannot be cured, but it can be effectively treated. Treatment of classical CAH starts soon after birth and is needed throughout the patient's life. People with classical CAH should have a team of healthcare providers, including specialists in pediatric endocrinology, uro-gynecologic surgery (for girls), psychology and genetics. People with classical CAH can have normal, fulfilling lives. Patients with non-classical CAH may not need any treatment, depending on their symptoms. Treatment must be individualized by doctors who have experience with this condition.
The primary goal of treating classical CAH is to reduce the excess androgen production and replace the deficient hormones. Proper treatment with the correct dosage of these hormones is crucial to preventing adrenal crisis and virilization. Daily tablets including glucocorticoids (to replace cortisol), mineralocorticoids (to replace aldosterone) and salt supplements may be prescribed, particularly in infancy. During times of high stress or illness adrenal glands are normally much more active. Therefore, when ill or after major surgery or stressful event, CAH patients must be closely monitored because their bodies will require more hormones to help the body recover and meet increased demands. During adulthood, individuals with CAH usually require fewer hormones than during childhood and puberty. Hormone levels need to be adjusted and monitored throughout the patient's life. The dose of glucocorticoids should be minimized to avoid development of Cushing's syndrome, a disorder characterized by a variety of symptoms and physical abnormalities including weight gain; skin, muscle and bone changes.
Female classical CAH patients also have the option of surgery to correct the appearance of ambiguous genitalia. Usually surgery is thought to be easier when performed within 2-6 months after birth. The choice to have the surgery should be reserved for infants with severe genital ambiguity, and is most often a joint decision of the parents and medical-surgical teams. Some parents choose to wait until their daughter is old enough to have a say in her surgery. Others feel the problem is severe and should be corrected immediately. If this is the case, finding a highly skilled pediatric urologic surgeon is of the utmost importance. This type of surgery has seen a great deal of improvement in terms of cosmetic appearance and functionality over the past few years. It is also highly recommended that families of girls who undergo this surgery have the option to receive psychological care.
Non-classical CAH on the other hand, is not life-threatening and relatively mild. People who have no obvious symptoms of non-classical CAH do not require surgery or treatment. If a patient with non-classical CAH begins to enter puberty too early, has early maturation of bones, or is female yet develops masculine features, glucocorticoids are recommended. Fertility problems can also be corrected with glucocorticoids and/or fertility drugs. Women who do not wish to conceive may also be prescribed oral contraceptives. Unlike severe forms of CAH, non-classical CAH patients are free to taper and stop treatment when symptoms go away.
Please refer to the Endocrine Society Clinical Practice Guidelines for additional information regarding diagnosis and treatment of CAH.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
(To become a member of NORD, an organization must meet established criteria and be approved by the NORD Board of Directors. If you're interested in becoming a member, please contact Susan Olivo, Membership Manager, at firstname.lastname@example.org.)
Wilson JD, Foster DW. Textbook of Endocrinology. 8th ed. Philadelphia, PA: W. B. Saunders Co; 1992:565-70, 907-15.
Berkow R, ed. The Merck Manual, 16th Ed. Merck Research Laboratories; 1992: 2224-26.
Wyngaarden JB, Smith LH, eds. Cecil Textbook of Medicine, 19th Ed. W.B. Saunders Co.; 1992:1331-33, 1377.
Wilson JD, Foster DW, eds. Textbook of Endocrinology, 8th Ed. W.B.Saunders Co.; 1992: 565-70.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133-60. http://www.endo-society.org/guidelines/upload/FINAL-Standalone-CAH-Guideline.pdf
Bachelot A, Chakthoura Z, Rouxel A, Dulon J, Touraine P. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res. 2008;69:203-11. http://www.ncbi.nlm.nih.gov/pubmed/18204267
Hughes IA, Houk C, Ahmed SF, Lee PA. LWPES Consensus Group; Consensus statement on management of intersex disorders. Arch Dis Child. 2006;91:554-63. http://adc.bmj.com/content/91/7/554.extract
Kashimada K, Ono M, Onishi T, Koyama S, Toyoura T, Imai K, Saisho S, Mizutani S. Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood. Endocr J. 2008;55:397-404. http://www.ncbi.nlm.nih.gov/pubmed/18385531
Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776-88. http://www.nejm.org/doi/full/10.1056/NEJMra021561
CARES Foundation. http://www.caresfoundation.org/productcart/pc/index.html Accessed on: January 16, 2012.
Hormone Foundation. http://www.hormone.org/ Accessed on:January 16, 2012.
Donohoue PA, Parker KL, Migeon CJ. Congenital adrenal hyperplasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease (OMMBID). Chap 159. New York, NY: McGraw-Hill. Available at www.ommbid.com. Accessed on:January 18, 2012.
Nimkarn, S and New MI. Updated:August 24, 2010. 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia.. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2012. Available at http://www.genetests.org. Accessed on:January 18, 2012.
Wilson, TA. Congenital Adrenal Hyperplasia. Updated Sept 17, 2010. www.emedicine.com/ped/topic48.htm Accessed on: January 16, 2012.
Report last updated: 2012/02/02 00:00:00 GMT+0